BioSoteria announced that its President and CEO Sally Van Doren, PharmD, will present at the 9th DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies, which takes place January 10-13, 2010, in Washington, DC. Dr. Van Doren will present on the topic of the Integrated Summary of Safety.
Emeryville, CA (PRWEB) November 18, 2009 -- BioSoteria, Inc., a drug safety service provider and training company, announced today that its President and Chief Executive Officer Sally Van Doren, PharmD, will present at the 9th Drug Information Association (DIA) Conference for Contemporary Pharmacovigilance and Risk Management Strategies. The meeting will take place January 10-13, 2010, in Washington, DC.
Dr. Van Doren will present on the topic of the Integrated Summary of Safety (ISS) during the session regarding Safety Reporting for Drugs and Biologics. Her talk will focus on the practical aspects of authoring the ISS, such as project planning, data pooling decisions, and integration points with the Common Technical Document and the product label.
"After authoring numerous safety analyses over the years, I have learned that the ISS is not as straight-forward as it appears in content requirements," said Dr. Van Doren. "I look forward to sharing my experience with this audience of drug safety professionals."
The DIA Conference for Contemporary Pharmacovigilance and Risk Management has become an important annual meeting for drug safety practitioners. The three-day program addresses regulatory activities and the complexities involved in maximizing the benefits and minimizing the risks of pharmaceuticals throughout all phases of development and marketed use. For more information, please visit the DIA website at www.diahome.org.
About Sally Van Doren, PharmD
Dr. Van Doren is the President, Chief Executive Officer and Founder of BioSoteria, the fastest-growing drug safety service provider and training company based on the West Coast. With more than twenty years of pharmaceutical industry experience, Dr. Van Doren has held leadership positions in drug safety and risk management, clinical development, and medical information services. She has been directly involved in numerous safety analyses for US and European product marketing applications and has advised many companies on a broad range of safety issues.
About BioSoteria, Inc.
BioSoteria is an innovative drug safety services and education provider to the biopharmaceutical industry. BioSoteria offers a wide range of consulting and operational services in clinical safety, postmarketing pharmacovigilance, and pharmaceutical risk management. To learn more about BioSoteria, please visit the company's website or call toll-free at 1-866-660-5553, extension 010.
Read the full story at http://www.prweb.com/releases/pharmacovigilance/conference/prweb3225234.htm.
Copyright©2009 Vocus, Inc.
All rights reserved